GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concert Pharmaceuticals Inc (NAS:CNCE) » Definitions » Net Margin %

Concert Pharmaceuticals (Concert Pharmaceuticals) Net Margin % : -361,300.00% (As of Sep. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Concert Pharmaceuticals Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Concert Pharmaceuticals's Net Income for the three months ended in Sep. 2022 was $-28.90 Mil. Concert Pharmaceuticals's Revenue for the three months ended in Sep. 2022 was $0.01 Mil. Therefore, Concert Pharmaceuticals's net margin for the quarter that ended in Sep. 2022 was -361,300.00%.

The historical rank and industry rank for Concert Pharmaceuticals's Net Margin % or its related term are showing as below:

CNCE' s Net Margin % Range Over the Past 10 Years
Min: -300735.71   Med: -307.67   Max: 66.47
Current: -300735.71


CNCE's Net Margin % is not ranked
in the Biotechnology industry.
Industry Median: -162.58 vs CNCE: -300735.71

Concert Pharmaceuticals Net Margin % Historical Data

The historical data trend for Concert Pharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concert Pharmaceuticals Net Margin % Chart

Concert Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 66.47 -533.31 -7,257.75 -946.17 -245.72

Concert Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4,913.08 -277,915.38 - -112,133.33 -361,300.00

Competitive Comparison of Concert Pharmaceuticals's Net Margin %

For the Biotechnology subindustry, Concert Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Concert Pharmaceuticals's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Concert Pharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where Concert Pharmaceuticals's Net Margin % falls into.



Concert Pharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Concert Pharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2021 is calculated as

Net Margin=Net Income (A: Dec. 2021 )/Revenue (A: Dec. 2021 )
=-80.051/32.578
=-245.72 %

Concert Pharmaceuticals's Net Margin for the quarter that ended in Sep. 2022 is calculated as

Net Margin=Net Income (Q: Sep. 2022 )/Revenue (Q: Sep. 2022 )
=-28.904/0.008
=-361,300.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Concert Pharmaceuticals  (NAS:CNCE) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Concert Pharmaceuticals Net Margin % Related Terms

Thank you for viewing the detailed overview of Concert Pharmaceuticals's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Concert Pharmaceuticals (Concert Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
65 Hayden Avenue, Suite 3000N, Lexington, MA, USA, 02421
Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop small-molecule drugs by incorporating new elements into known molecules or by leveraging the currently approved drugs to be used for new treatments. The pipeline consists of small molecules designed for oral administration to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer's agitation.
Executives
James V Cassella officer: Chief Development Officer 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Marc A. Becker officer: CFO, PFO 175 CROSSING BLVD., 4TH FLOOR, FRAMINGHAM MA 01702
Nancy Stuart officer: Chief Operating Officer 99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Jeffrey A Munsie officer: Chief Legal Officer CONCERT PHARMACEUTICALS, INC., 65 HAYDEN AVENUE, SUITE 3000N, LEXINGTON MA 02421
Roger D Tung director, officer: Chief Executive Officer 99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Peter Barton Hutt director
Thomas G Auchincloss director C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Richard Aldrich director 1365 MAIN STREET, WALTHAM MA 02451
Heek Christi Van director 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Jesper Hoeiland director C/O RADIUS HEALTH, INC., 950 WINTER STREET, WALTHAM MA 02451
Ronald W Barrett director C/O XENOPORT, INC., 3410 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Wendall Wierenga director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Wilfred E Jaeger director C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Meghan Fitzgerald director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511

Concert Pharmaceuticals (Concert Pharmaceuticals) Headlines

From GuruFocus

Concert Pharmaceuticals Reports Third Quarter 2022 Financial Results

By Business Wire Business Wire 11-07-2022